Cardiotoxicity: a challenge for modern oncology
Автор: Kit Oleg I., Frantsiyants Elena M., Djenkova Lubov A., Katelnitskaya Oksana V., Shikhlyarova Alla I., Sagakyants Aleksandr B., Verenikina Ekaterina V., Gevorkyan Yuriy А., Fomenko Yuriy А., Trifanov Vladimir S., Shevchenko Aleksey N.
Журнал: Cardiometry @cardiometry
Рубрика: Review
Статья в выпуске: 13, 2018 года.
Бесплатный доступ
The article provides a modern vision of the problem of cardiotoxicity in oncology. Integrity and generality of nodal pathogenetic events in the body in case of carcinogenesis, antitumor therapy and cardiopathology are caused by similar mechanisms at different hierarchical levels. Identity of potential risk factors, including inflammation, aging, obesity, diabetes and smoking, has been noted. Similarly, in the development of metabolic syndrome and carcinogenesis, the level of growth factors (IGF-1), neoangiogenesis, hormones and other triggers of oncological and cardiovascular pathology is increasing. It is important that a variety of clinical manifestations of cardiotoxicity are due to the rapid expansion of the number of therapeutic options for effects. This thesis is illustrated by vivid examples of the use of anthracycline-based drugs whose mechanism of action is aimed at damaging genetic targets. The use of monoclonal antibodies - trastuzumab, is directed against HER2 / ErB2 receptors in breast cancer and is accompanied by distinct signs of cardiotoxicity especially in the elderly...
Cardiotoxicity, cardiopathology, carcinogenesis, trastuzumab, tissue homeostasis, antitumor effect
Короткий адрес: https://sciup.org/148308857
IDR: 148308857 | DOI: 10.12710/cardiometry.2018.13.814
Список литературы Cardiotoxicity: a challenge for modern oncology
- DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman and Rosenberg's cancer: principles and practice of oncology. 10th. River-woods (IL): Wolters Kluwer; 2014
- Blaes A, Prizment A, Koene RJ, Konety S. Cardio-oncology Related to Heart Failure Common Risk Factors Between Cancer and Cardiovascular Disease. Heart Failure Clinics. 2017;13(2):367-80. http://doi. org/10.1016/j.hfc.2016.12.006
- de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56.
- Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S-60S
- Prabhu SR, Wilson DF. Evidence of Epstein-barr virus association with head and neck cancers: a review. J Can Dent Assoc. 2016;82:g2.
- Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248(3):171-83.
- Woodward J. Improving outcomes of refractory celiac disease -current and emerging treatment strategies. Clin Exp Gastroenterol. 2016;9:225-36.
- Zeineddine N, Khoury LE, Mosak J. Systemic sclerosis and malignancy: a review of current data. J Clin Med Res. 2016;8(9):625-32
- Parrinello CM, Lutsey PL, Ballantyne CM, et al. Sixyear change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J. 2015;170(2):380-9
- Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104-14.
- Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-78.
- Emanuela F, Grazia M, Marco de R, et al. Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab. 2012;2012:476380
- Luft VC, Schmidt MI, Pankow JS, et al. Chronic inflammation role in the obesity-diabetes association: a case-cohort study. Diabetol Metab Syndr. 2013;5(1):31
- Bjorge T, Stocks T, Lukanova A, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol. 2010;171(8):892-902
- Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care. 2013;36(Suppl 2):S233-9
- Haggstrom C, Rapp K, Stocks T, et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One. 2013;8(2):e57475
- Mendonca FM, de Sousa FR, Barbosa AL, et al. Metabolic syndrome and risk of cancer: which link? Metabolism. 2015;64(2):182-9.
- Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflam. and metab. in obesity-related cardiov. dis. J Am Coll Cardiol. 2008;52(15):1201-10.
- Chen C, Chang YC, Lan MS, et al. Corrigendum] leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/akt signaling pathways. Int J Oncol. 2016;49(2):847
- Satija A, Spiegelman D, Giovannucci E, et al. Type 2 diabetes and risk of cancer. BMJ. 2015;350:g7707
- Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607
- Becker MA, Ibrahim YH, Oh AS, et al. Insulin receptor substrate adaptor proteins mediate prognostic gene expression profiles in breast cancer. PLoS One. 2016;11(3):e0150564
- Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.
- Nelson ER, Wardell SE, Jasper JS, et al. 27-hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094-8.
- Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast cancer. N Engl J Med. 2014;370(6):572-3
- Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality-beyond established causes. N Engl J Med. 2015;372(7):631-40
- Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the prevention of cardiovascular disease section leadership council and early career councils of the american college of cardiology. J Am Coll Cardiol. 2015;66(12):1378-91. http://dx.doi.org/10.1016/j. jacc.2015.07.037.
- Weaver KE, Foraker RE, Alfano CM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv. 2013;7(2):253-61
- Whitlock MC, Yeboah J, Burke GL, et al. Cancer and its association with the development of coronary artery calcification: an assessment from the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2015;4(11)
- Davis MK, Rajala JL, Tyldesley S, et al. The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia, Canada. J Oncol. 2015;2015:820403
- Morote J, Gomez-Caamano A, Alvarez-Ossorio JL, et al. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol. 2015;193(6):1963-9
- Zheng P, Li J, Kros JM. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research practice gaps, challenges, and insights. Medicinal Research Reviews. 2018;38(1):325-76. http://doi.org/10.1002/med.21463
- Murphy SL, Xu J, Kochanek KD: Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61(4):1-117
- Markman TM, Markman M. Cardio-Oncology: mechanisms of cardiovascular toxicity. F1000Research. 2018;7(113). http://doi.org/10.12688/ href='contents.asp?titleid=51456' title='F1000Research'>F1000Research.12598.1
- Coviello JS, Cardiac side effects of targeted therapies. Semin Oncol Nurs. 2014;30(3):175-82
- Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457-67 DOI: 10.1056/NEJMra1100265
- Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-20 DOI: 10.1016/j.jacc.2009.03.095
- Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214-20. 10.2174/157340311799960645
- De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121(2):276-92. 10.1161/CirculationAHA.109.89577
- Horie T, Ono K, Nishi H, et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res. 2010;87(4):656-64. 10.1093/cvr/cvq148
- Maurea N, Coppola C, Ragone G, et al. Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. J Cardiovasc Med (Hagerstown). 2010;11(12):861-8. 10.2459/JCM.0b013e328336b4c1
- Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without Trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol. 2009;27:5685-92
- Slamon D, Eiermann W, Robert N, et al. Adjuvant Trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-83
- Romon EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus Trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:3792-9
- Chavez-MacGregor M, N Zhang, TA Buchholz, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013;31:4222-8.
- Chen J, Long JB, Hurria A, et al. Incidence of heart failure or cardiomyopathy after adjuvant Trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60:2504-12
- Tarantini L, Gori S, Faggiano P, et al. Adjuvant Trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: A multicenter cohort analysis. Ann Oncol. 2012;23:3058-63
- Chavez-MacGregor Mariana, Jiangong Niu, Ning Zhang, et al. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. Journal of Clinical Oncology. 2015;33(19):2176-83. PMID: 25964256 DOI: 10.1200/JCO.2014.58.9465
- Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4:261 DOI: 10.21037/atm.2016.04.01
- Tocchetti CG, Cadeddu C, Di Lisi D, et al. From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview. Antioxid Redox Signal. 2017 DOI: 10.1089/ars.2016.6930
- Ledford H. Cocktails for cancer with a measure of immunotherapy. Nature. 2016;532:162-4 DOI: 10.1038/532162a
- Dong J, Chen H. Cardiotoxicity of Anticancer Therapeutics. Frontiers in Cardiovascular Medicine. 2018;5(9). http://doi.org/10.3389/fcvm.2018.00009
- Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50 DOI: 10.1186/s40425-016-0152-y
- Cheng F, Loscalzo J. Autoimmune cardiotoxicity of cancer immunotherapy. Trends Immunol.2017;38:77-8 DOI: 10.1016/j.it.2016.11.007
- Jain V, Bahia J, Mohebtash M, Barac A. Cardiovascular complications associated with novel cancer immunotherapies. Curr Treat Options Cardiovasc Med. 2017;19:36 DOI: 10.1007/s11936-017-0532-8
- Johnson DB, Balko JM, Compton ML, et al. Fulminant myoc. with comb. imm. checkp. blockade. N Engl J Med. 2016;375:1749-55 DOI: 10.1056/NEJMoa1609214
- Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13:370-83 DOI: 10.1038/nrclinonc.2016.36
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34 DOI: 10.1056/NEJMoa1504030
- Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.10.1126/scitranslmed.3008226
- Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-95 DOI: 10.1038/sj.bjc.6603813
- Di Lisi D, Madonna R, Zito C, et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. Int J Cardiol. 2017;227:11-7. doi:10.1016/j.ijcard.2016.11.174
- Tromp J, Steggink LC, Van Veldhuisen DJ, Gietema JA, van der Meer P. Cardio-oncology: progress in diagnosis and treatment of cardiac dysfunction. Clin Pharmacol Ther. 2017;101:481-90 DOI: 10.1002/cpt.614
- Damrongwatanasuk R, Fradley MG. Cardiov. complic. of targ. ther. for chronic myeloid leuk. Curr Treat Opt. Cardiov. Med. 2017;19:24 DOI: 10.1007/s11936-017-0524-8
- Pun SC, Neilan TG. Cardiovascular side effects of small molecule therapies for cancer. Eur Heart J. 2016;37:2742-5 DOI: 10.1093/eurheartj/ehw361
- Varricchi G, Ameri P, Cadeddu C, et al. Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Frontiers in Physiology. 2018;9(167). http://doi.org/10.3389/fphys.2018.00167
Статья обзорная
